Screener
D&A at other companies
Other financials
Where this comes from
Reported directly by Maze Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:Depreciation.
The source filing: Maze Therapeutics’s 10-Q, filed August 11, 2026.
- Filed
- Aug 11, 2026, 4:48 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-344903
| Line item | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|
| Operating activities | ||
| Net loss | $(68,935) | $(66,465) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation expense | 835 | 1,333 |
| Stock-based compensation expense | 16,296 | 6,463 |
| Non-cash lease expense | 1,674 | 1,543 |
| Amortization of premiums on marketable securities, net | 5 | — |
| Amortization of debt discount and debt issuance costs | 498 | — |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Maze Therapeutics's D&A?
- Maze Therapeutics (MAZE) reported D&A of $391K in Q2 2026.
- How has Maze Therapeutics's D&A changed year-over-year?
- Maze Therapeutics's D&A decreased by 39.8% year-over-year, from $649K to $391K.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.
Ask your AI about Maze Therapeutics's d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude